Process optimization of large-scale production of recombinant adeno-associated vectors using dielectric spectroscopy

被引:34
作者
Negrete, Alejandro
Esteban, Geoffrey
Kotin, Robert M.
机构
[1] NHLBI, NIH, Lab Biochem Genet, Bethesda, MD 20892 USA
[2] FOGALE Nanotech, F-30900 Nimes, France
关键词
adeno-associated vectors; gene therapy; dielectric spectroscopy; large-scale; bioprocessing; harvesting time;
D O I
10.1007/s00253-007-1030-9
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A well-characterized manufacturing process for the large-scale production of recombinant adeno-associated vectors (rAAV) for gene therapy applications is required to meet current and future demands for pre-clinical and clinical studies and potential commercialization. Economic considerations argue in favor of suspension culture-based production. Currently, the only feasible method for large-scale rAAV production utilizes baculovirus expression vectors and insect cells in suspension cultures. To maximize yields and achieve reproducibility between batches, online monitoring of various metabolic and physical parameters is useful for characterizing early stages of baculovirus-infected insect cells. In this study, rAAVs were produced at 40-l scale yielding similar to 1 x 10(15) particles. During the process, dielectric spectroscopy was performed by real time scanning in radio frequencies between 300 kHz and 10 MHz. The corresponding permittivity values were correlated with the rAAV production. Both infected and uninfected reached a maximum value; however, only infected cell cultures permittivity profile reached a second maximum value. This effect was correlated with the optimal harvest time for rAAV production. Analysis of rAAV indicated the harvesting time around 48 h post-infection (hpi), and 72 hpi produced similar quantities of biologically active rAAV. Thus, if operated continuously, the 24-h reduction in the production process of rAAV gives sufficient time for additional 18 runs a year corresponding to an extra production of similar to 2 x 10(16) particles. As part of large-scale optimization studies, this new finding will facilitate the bioprocessing scale-up of rAAV and other bioproducts.
引用
收藏
页码:761 / 772
页数:12
相关论文
共 47 条
[11]   Recent developments in recombinant AAV-mediated gene therapy for lung diseases [J].
Flotte, TR .
CURRENT GENE THERAPY, 2005, 5 (03) :361-366
[12]  
FUKUCHI KI, 2006, NEUROBIOL DIS, V29, P19
[13]   Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge [J].
Galarza, JM ;
Latham, T ;
Cupo, A .
VIRAL IMMUNOLOGY, 2005, 18 (02) :365-372
[14]  
Gentilomi G, 2006, NEW MICROBIOL, V29, P19
[15]   Systemic delivery of genes to striated muscles using adeno-associated viral vectors [J].
Gregorevic, P ;
Blankinship, MJ ;
Allen, JM ;
Crawford, RW ;
Meuse, L ;
Miller, DG ;
Russell, DW ;
Chamberlain, JS .
NATURE MEDICINE, 2004, 10 (08) :828-834
[16]   Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications [J].
Grieger, JC ;
Samulski, RJ .
GENE THERAPY AND GENE DELIVERY SYSTEMS, 2005, 99 :119-145
[17]   Novel tools for production and purification of recombinant adenoassociated virus vectors [J].
Grimm, D ;
Kern, A ;
Rittner, K ;
Kleinschmidt, JA .
HUMAN GENE THERAPY, 1998, 9 (18) :2745-2760
[18]   Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene [J].
Halbert, CL ;
Allen, JM ;
Miller, AD .
NATURE BIOTECHNOLOGY, 2002, 20 (07) :697-701
[19]   Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors [J].
Handa, A ;
Muramatsu, S ;
Qiu, JM ;
Mizukami, H ;
Brown, KE .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :2077-2084
[20]  
Herzog Roland W, 2004, Methods Mol Biol, V246, P179